SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: There is limited number of studies regarding the predictive factors for prognosis of Pulmonary thromboembolism (PE), which is a recurrent disease and has many chronicle sequelas. The aim of this study is to investigate the prognosis of PTE (in terms of recurrence, complications, survival and mortality) and factors affecting the prognosis.
METHODS: Patients who were hospitalized for PTE between January 1998-January 2010, whose files consisted valid clinical and contact information were involved in the study (n: 245). The information regarding PTE treatment, recurrence, survival, complications and development of malignancy were recorded.
RESULTS: Mean treatment time was10.4±13.4 months. Recurrence and mortality rates were 13.0% and 14.3% respectively. Co-existent cancer (HR: 2.711, p=0.04) and immobility (HR: 2.846, p=0.014) were independent predictors of mortality. Atherosclerotic cardiac disease (OR: 2.4, p=0.04) and diagnosis of DVT in follow-up (OR: 23, p=0.0001) were independent predictors of recurrent PE. PE complications like chronic thromboembolic pulmonary hypertension (%0.8) and chronic respiratory failure (%3.7) were more frequently observed in patients with older age, more comorbid conditions and recurrent PE. Malignity was diagnosed in 5.7% of idiopathic cases during the follow up, however this ratio was not different from the patients with risk factors for PE.
CONCLUSIONS: Pulmonary thromboembolism is an important disease with high mortality rate and severe complications.
CLINICAL IMPLICATIONS: To improve the personal and financial outcomes of the disease all risk factors affecting the prognosis (recurrence, complications and mortality) should be investigated to develop more effective treatment and follow-up strategies.
DISCLOSURE: The following authors have nothing to disclose: Fusun KolatKirkpantur, I.Kivilcim Oguzulgen, Numan Ekim
No Product/Research Disclosure Information